204 related articles for article (PubMed ID: 4074429)
1. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system.
Shintani S; Toba Y; Suzuki S; Ninomiya S; Umezato M; Hiyama T
Arzneimittelforschung; 1985; 35(7A):1157-62. PubMed ID: 4074429
[TBL] [Abstract][Full Text] [Related]
2. General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: Effect on the peripheral organs.
Shintani S; Watanabe K; Kawamura K; Mori T; Tani T; Toba Y; Sasabe H; Nakagiri N; Hongoh O; Fujita S
Arzneimittelforschung; 1985; 35(7A):1163-72. PubMed ID: 3000392
[TBL] [Abstract][Full Text] [Related]
3. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
Kito G; Morimoto S; Shiomi M
Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
[TBL] [Abstract][Full Text] [Related]
4. [Effects of suloctidil on the central and peripheral nervous systems].
Nishi H; Watanabe T; Mori M
Nihon Yakurigaku Zasshi; 1983 Sep; 82(3):191-212. PubMed ID: 6319248
[TBL] [Abstract][Full Text] [Related]
5. General pharmacological properties of the new vasodilator flosequinan.
Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
[TBL] [Abstract][Full Text] [Related]
6. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system.
Murata T; Sakaya S; Hoshino T; Umetsu T; Hirano T; Nishio S
Arzneimittelforschung; 1989 Aug; 39(8):860-6. PubMed ID: 2510742
[TBL] [Abstract][Full Text] [Related]
7. Effect of cilostazol on platelet aggregation and experimental thrombosis.
Kimura Y; Tani T; Kanbe T; Watanabe K
Arzneimittelforschung; 1985; 35(7A):1144-9. PubMed ID: 4074426
[TBL] [Abstract][Full Text] [Related]
8. General pharmacological properties of the main metabolite of flosequinan.
Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part II: Central and peripheral nervous systems.
Hirohashi M; Takasuna K; Kasai Y; Usui C; Kojima H
Arzneimittelforschung; 1991 Jan; 41(1):19-24. PubMed ID: 1675569
[TBL] [Abstract][Full Text] [Related]
10. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
Hirotsu I; Kihara T; Nakamura S; Hattori Y; Hatta M; Kitakaze Y; Takahama K; Hashimoto Y; Miyata T; Ishihara T
Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380
[TBL] [Abstract][Full Text] [Related]
11. General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol.
Hirohashi M; Takasuna K; Tamura K; Yamaguchi K; Maekawa K; Yamada S; Iwasaki S; Yoshida M; Nomura M; Taguchi K
Arzneimittelforschung; 1990 Jul; 40(7):735-46. PubMed ID: 1977393
[TBL] [Abstract][Full Text] [Related]
12. General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on central nervous and sensory systems and other functions.
Yamamoto S; Takemori E; Hasegawa Y; Nakao K; Inukai T; Nomura M; Morino K; Tsuchiyama M; Hasegawa K; Ikeda H
Arzneimittelforschung; 1991 Jun; 41(6):602-7. PubMed ID: 1930347
[TBL] [Abstract][Full Text] [Related]
13. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation.
Kawamura K; Watanabe K; Kimura Y
Arzneimittelforschung; 1985; 35(7A):1149-54. PubMed ID: 4074427
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological properties of procaterol, a newly synthetized, specific beta 2-adrenoceptor stimulant. Part I. Effects on the CNS (author's transl)].
Hashimoto K; Shintani S; Yamashita S; Tei S; Takai M; Tsutsui M; Kawamura K; Ohkawa T; Hiyama T; Yabuuchi Y
Nihon Yakurigaku Zasshi; 1979 Apr; 75(3):271-89. PubMed ID: 43821
[TBL] [Abstract][Full Text] [Related]
15. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
[TBL] [Abstract][Full Text] [Related]
16. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 2nd communication: Effects on central nervous and sensory systems and on the other functions.
Matsuno Y; Hori H; Oka M; Nakamura H; Ito T; Kadokawa T
Arzneimittelforschung; 1986; 36(1):62-8. PubMed ID: 3513778
[TBL] [Abstract][Full Text] [Related]
17. General pharmacology of recombinant human basic fibroblast growth factor.
Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
[TBL] [Abstract][Full Text] [Related]
18. Effects of azelastine hydrochloride, a novel anti-allergic drug, on the central nervous system.
Kaneko T; Kitahara A; Ozaki S; Takizawa K; Yamatsu K
Arzneimittelforschung; 1981; 31(8):1206-12. PubMed ID: 6117290
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological studies of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). (5) Action of M73101 on the central nervous system (author's transl)].
Sato M
Nihon Yakurigaku Zasshi; 1979 Oct; 75(7):695-706. PubMed ID: 575516
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of amezinium, a novel antihypotensive drug. VI. Effect on central nervous functions.
Teschendorf HJ; Kretzschmar R; Kreiskott H; Weifenbach H
Arzneimittelforschung; 1981; 31(9a):1580-8. PubMed ID: 7197973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
